Seres Therapeutics, Inc.
MCRB
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). Iā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.03
Price+4.14%
$0.20
1Y
Price
Market Cap
$48.710m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-5344.1%
EBITDA Margin-5562.3%
Net Profit Margin-4569.8%
Free Cash Flow Margin-5344.1%
EBITDA Margin-5562.3%
Net Profit Margin-4569.8%
Free Cash Flow MarginRevenue
$1.147m
+45.4%
1y CAGR+15.1%
3y CAGR+11.3%
5y CAGREarnings
-$46.899m
-923.4%
1y CAGR-282.8%
3y CAGR-198.5%
5y CAGREPS
-$5.17
-907.8%
1y CAGR-270.2%
3y CAGR-187.2%
5y CAGRBook Value
$26.499m
$117.618m
Assets$91.119m
Liabilities$80.499m
DebtDebt to Assets
68.4%
-1.9x
Debt to EBITDAFree Cash Flow
-$42.371m
-4998.4%
1y CAGR-1638.9%
3y CAGR-1217.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company